Other Briefings
New EV Scheme Paves Way for Global Auto Majors to Invest in India
India has launched the official application portal for its new electric vehicle (EV) manufacturing scheme—SPMEPCI. Eligible automakers can submit applications between June 24 and October 21, 2025.
Karnataka Notifies Peenya as Special Investment Region to Boost Industrial Growth
On June 11, 2025, Karnataka designated Bengaluru’s Peenya Industrial Area as its 18th Special Investment Region (SIR), authorizing KIADB to lead governance, infrastructure upgrades, and investment promotion in a major MSME hub.
India’s 2025 Maritime Push with US$20 Billion Investment and Global Ties
India has unveiled a US$20 billion maritime plan with global partners to advance green shipping, port digitization, and sectoral investments.
India’s Climate Finance Taxonomy in 2025: An Overview
India’s draft Climate Finance Taxonomy aims to guide green investments, prevent greenwashing, and support its net zero 2070 target across key sectors.
India’s AI Infrastructure and Emerging Market Leadership: An Outlook
India’s artificial intelligence (AI) sector is set to add US$400 billion to the economy by 2030, propelled by favorable policies, rising foreign direct investments (FDI), and surging demand for digital services.
FTAs and FDI Fuel Expansion in India’s Luxury Car Segment
India’s luxury car market is expanding rapidly, driven by EV adoption, foreign investment, and trade policy reforms. Explore key trends, FDI data, OEM strategies, and the impact of FTAs shaping the future of the sector.
India’s Manufacturing Sector Poised for Growth Amid Global Trade Shifts: Report
According to a market intelligence report released by S&P Global on May 19, 2025, India’s manufacturing sector is gaining momentum, positioning it as an attractive hub for foreign investors.
Indian Pharma on Alert as US Slashes Drug Prices Under MFN Policy
On May 12, 2025, the Trump administration mandated pharmaceutical companies to reduce the prices of drugs sold in the US under the MFN pricing model. This could affect the Indian pharma sector, a key supplier to the US market.
